Sohonos Capsule
NDC Package 15054-0010-1
Package Information
Sohonos (palovarotene) capsules is sOHONOS is indicated for the reduction in volume of new heterotopic ossification in adults and pediatric patients aged 8 years and older for females and 10 years and older for males with fibrodysplasia ossificans progressiva (FOP). This formulation utilizes a capsule delivery system. Marketed by Ipsen Biopharmaceuticals, Inc., this product is identified by NDC 15054-0010 and is authorized under FDA application NDA215559.
Identification & Billing
- RxCUI: 2663960 - palovarotene 1 MG Oral Capsule
- RxCUI: 2663966 - sohonos 1 MG Oral Capsule
- RxCUI: 2663966 - palovarotene 1 MG Oral Capsule [Sohonos]
- RxCUI: 2663966 - Sohonos 1 MG Oral Capsule
- RxCUI: 2663968 - palovarotene 1.5 MG Oral Capsule
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 15054 - Ipsen Biopharmaceuticals, Inc.
- 15054-0010 - Sohonos
- 15054-0010-1 - 1 BLISTER PACK in 1 CARTON / 14 CAPSULE in 1 BLISTER PACK
- 15054-0010 - Sohonos
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 15054-0010-1 identifies a specific commercial package of 1 blister pack in 1 carton / 14 capsule in 1 blister pack of Sohonos, a human prescription drug labeled by Ipsen Biopharmaceuticals, Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This capsule is formulated for oral use and contains palovarotene as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Ipsen Biopharmaceuticals, Inc. on August 16, 2023. The current certification is valid through December 31, 2026.
How is this Ipsen Biopharmaceuticals, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 15054001001. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.